CS Paper Radar

Sensitivity-driven Personalization of a Glucoregulatory Model for Digital Twin Therapeutics in Type 1 Diabetes

Clara Escorihuela-Altaba, Vihangkumar V. Naik, Eleonora Manzoni, Jose Garcia-Tirado

eess.SY ·submitted 2026-09-25 13:38 UTC · v1

Abstract

Digital twins are increasingly used in diabetes research, but reproducing individual glucose dynamics requires accurate identification of glucoregulatory model parameters. Traditional sensitivity analysis can identify influential parameters, yet a ranking based on limited conditions may miss parameters that matter during specific disturbances or for particular individuals. We therefore examine both the magnitude and timing of parameter influence across dynamic input-output conditions and assess whether a common ranking holds across participants. We analyze the Hovorka glucoregulatory model using data from 192 participants receiving automated insulin delivery therapy in the Type 1 Diabetes and Exercise Initiative dataset. We extend Sobol sensitivity analysis to time series and rank parameter influence under four conditions: full-day profiles, isolated meal disturbances, insulin bolus injections, and postprandial responses. We combine the condition-specific results into a global ranking and use it to select parameters for participant-specific identification. Compared with population parameters, identification restricted to the sensitivity-derived subset reduces the root mean square error of 60-minute glucose predictions by 60%, to approximately 31 mg/dL. These findings suggest that a global ranking can capture parameter influence across individuals and dynamic conditions. By narrowing the parameters requiring identification, this approach reduces computational cost and could accelerate the development of personalized diabetes digital twins.

Closest papers

Nearest neighbours by meaning across the whole index.

Evaluating Type-1 Diabetes Digital Twins by Decision Quality

cs.LG ·2026-10-22 ·Victor Li, Owen Tucker, Michael S. Hughes, Temiloluwa Prioleau, Shengpu Tang
code/data similarity 0.67
Abstract · 12 pages, 1 figure, 7 tables. Code: https://github.com/Veeeeeee7/T1D-Digital-Twin-Benchmark

A digital twin (DT) for type 1 diabetes (T1D) can predict how an individual's blood glucose will respond to different insulin treatments without actually trying them. For each treatment, downstream statistics of predicted glucose trajectories, such as glycemic risk, can be computed to guide clinical decisions. However, the quality of DTs is usually measured by the accuracy of their predicted glucose trajectories, which may not reflect the quality of the downstream treatment decisions they inform. In this work, we directly evaluate DTs by this decision quality on downstream treatment ranking, i.e., whether a DT predicts glucose trajectories that can be used to rank candidate treatments as the real patient would. We present an evaluation protocol over 30 virtual patients from the FDA-accepted UVA/Padova model, each simulated under 21 different basal-bolus treatments. For each patient, a DT is fitted under one treatment and then produces glucose trajectories for the remaining 20 treatments. Our results show that prediction accuracy and decision quality disagree. A baseline that models the average patient, never seeing the individual's glucose data, has the lowest prediction accuracy of all six methods (RMSE: 63.6 mg/dL) but ranks treatments with the second-highest mean Spearman (0.766), while a black-box neural network that predicts glucose nearly twice as accurately (RMSE: 32.9 mg/dL) ranks them no better than a random ordering of the 20 treatments (0.049 Spearman). Therefore, selecting a DT based on prediction accuracy alone can prefer one that recommends treatments at chance, and decision quality must be evaluated directly rather than assumed to follow from prediction accuracy.

0.34

It's All in the Way You Say It: The Role of Information Representation in LLM-Based Glycemic-Event Prediction

cs.AI ·2026-09-08 ·Andrea Apicella, Pasquale Arpaia, Matteo Orefice, Andrea Pollastro, Roberto Prevete
similarity 0.65
Abstract · Submitted to a journal for peer-review

Large Language Models (LLMs) are increasingly being investigated for physiological time-series prediction, yet their effectiveness may depend not only on the model itself, but also on how physiological information is represented and presented at inference time. This study investigates prompt-based general-purpose LLMs for postprandial hyperglycemia and hypoglycemia prediction in individuals with type 1 diabetes. Using the OhioT1DM dataset, we evaluate multiple open-weight LLMs under zero-shot and few-shot inference across prediction horizons of 30, 60, and 90 minutes. The analysis varies both the textual representation of the available physiological information and the amount of information exposed to the model, ranging from glucose observations alone to derived descriptors and additional contextual variables related to insulin, meals, carbohydrates, and physical activity. Performance is compared with conventional patient-specific supervised models and with Gluco-LLM, a language-model-based architecture explicitly adapted to glucose time-series forecasting. Results show a marked task-dependent behavior. Conventional supervised models achieve the strongest performance for hyperglycemia prediction, whereas the best observed prompt-based LLM configurations improve performance for hypoglycemia across all investigated horizons. The effectiveness of prompt-based inference is also strongly influenced by how physiological information is represented, while providing additional contextual information does not lead to a systematic improvement. Overall, these findings highlight physiological information representation as a central design factor in prompt-based LLM approaches to glycemic-event prediction.

0.35

Reliability-Aware Short-Term Glycemic Risk Prediction Using an Anchor-Based Comparative Framework of Sequence, Multimodal, and State-Updating Digital-Twin Models

cs.LG cs.AI ·2026-10-26 ·Pir Bakhsh Khokhar, Carmine Gravino, Fabio Palomba
similarity 0.64
Abstract · 36 pages, including figures, tables, and references. Research article on reliability-aware glycemic-risk prediction using sequence models an…

Anticipating short-term hypoglycemic and hyperglycemic risk is essential for proactive diabetes management. However, existing machine learning approaches often use inconsistent evaluation protocols and emphasize predictive performance over reliability. This study introduces an anchor-based benchmarking framework integrating longitudinal glucose sequences and multimodal patient information. Using the T1DiabetesGranada dataset, 5,503,441 standardized prediction anchors were constructed from 736 individuals with type 1 diabetes to evaluate hypoglycemia and hyperglycemia prediction at 30-, 60-, and 120-minute horizons. Three neural architectures, a Hybrid LSTM-Transformer, a Multimodal Digital Twin, and a State-Updating Digital Twin with gap-aware longitudinal state progression, were compared under identical patient-level validation protocols. Beyond predictive performance, the evaluation examined calibration, classification thresholds, explanation reliability, cross-model disagreement, and robustness to controlled perturbations. No statistically significant predictive differences were observed after Holm correction, although the models exhibited complementary reliability characteristics. The Multimodal Digital Twin achieved the lowest mean Brier score, while the State-Updating Digital Twin demonstrated the lowest mean expected calibration error (ECE-10). The Hybrid LSTM-Transformer showed strong explanation faithfulness and stability under its temporal attribution protocol. These findings highlight the importance of evaluating digital-twin models beyond predictive accuracy and emphasize the need for reliability assessment and external validation before clinical deployment.

0.24

Joint Modeling of Conditional Mean and Variability in Multilevel Functional Data: Application to Postprandial Glucose Trajectories in the AEGIS Study

cs.LG stat.MLstat.APstat.ME ·2026-11-05 ·Yang Xiao, Francisco Gude, Marcos Matabuena
similarity 0.63
Abstract

Functional data analysis provides a framework for studying time-varying associations between covariates and high-frequency biological signals. In digital health, participants often contribute repeated functional trajectories, yet existing multilevel regression methods largely focus on the conditional mean, overlooking variability and its role in biological heterogeneity. We propose a heteroskedastic functional mixed-effects regression framework that jointly models the conditional mean and variance of repeated trajectories, with participant-specific random effects in both components. We also develop a participant-level bootstrap to quantify uncertainty in estimated functional parameters. We apply the method to postprandial glucose trajectories from the AEGIS study. Premeal glucose, carbohydrate intake, and meal type show distinct time-dependent associations with glucose variability, whereas HbA1c is more strongly associated with the conditional mean than with variability. Substantial between-participant differences in residual variability remain even after accounting for observed covariates. These findings show that modeling conditional variability alongside the mean provides insights into glucose regulation and individual heterogeneity that mean-focused analyses may miss. More broadly, the proposed framework enables joint characterization of average responses, variability, and participant-specific heterogeneity in repeated biological signals.

0.23

FairGlucose: A CGM Fairness Benchmark Reveals Subgroup Disparities Hidden in Population-Level Validation

cs.CY cs.AI ·2026-08-18 ·Junjie Luo, Xuzhe Zhi, Rui Han, Abhimanyu Kumbara, Anand K. Iyer +3 more
benchmark similarity 0.61
Abstract

As CGM-based AI tools approach clinical deployment, whether their accuracy is equitable across patient demographics remains insufficiently tested. To enable this evaluation, we constructed FairGlucose, a 300-patient CGM cohort balanced across 12 demographic strata (age x gender x type 1/type 2 diabetes), with 132,480 forecasting samples and 3,945 unique behavioral events (meals, exercise, medication) logged by 81 patients. Benchmarking 33 models across four families on 2-hour glucose forecasting, we find that population-level external validation can conceal substantial subgroup disparities. Aggregate out-of-distribution metrics appear stable (approximately 1.0), yet subgroup-level ratios range from 0.8 to 1.4, with T1D patients showing 6 mg/dL higher prediction error than T2D (p < 0.001). This disparity persists across all 33 models, suggesting a property of the prediction task rather than any single architecture. Further analysis shows that subgroup performance gaps align with the proportion of clinically hard cases, and that input-length sensitivity varies across demographics, motivating personalized configurations. Frontier LLMs underperform specialized neural models by 1-6 mg/dL; behavioral events contribute negligibly (approximately 0.1 mg/dL) even under oracle event access. These findings establish that population-level validation alone is insufficient for equity assessment of digital health AI, motivating subgroup-disaggregated reporting as a default standard.

0.29

GlucoPRISM: Protocol-Supervised Pretraining for Cross-Cohort Glucose Transfer

cs.LG ·2026-10-08 ·Adinath Madhavrao Dukre, Abdullah Mohammad, Yifan Lu, Eran Segal, Ahmed Metwally +1 more
similarity 0.60
Abstract

Continuous glucose monitoring (CGM) foundation models encode each day as one vector that mixes who the person is, what happened that day and how the sensor measured it, so measurement differences travel with the representation into new cohorts. We ask whether pretraining can place the measurement component that harms transfer in known coordinates, so that deployment drops them with a fixed projection and no target data. GlucoPRISM supervises a GlucoFM backbone with response contracts, rules for how each part of the representation should change when only the day or only the sensor changes: a 64-dimensional Trait band should change with neither, a 48-dimensional State band only across days, and a 16-dimensional Sensor band should track the device. Synthetic sensor views calibrated on paired Dexcom and Libre recordings, different-day pairs and glucose-summary targets supply this supervision without clinical labels. Across twelve cross-cohort directions, dropping the Sensor band from the same frozen encoder raises mean transfer AUROC from 68.75 to 73.57, against 69.3 for GlucoFM. The gain has two parts. Into CGMacros, the one target cohort recorded with two sensor types, filtering adds 11 to 19 points, and this holds when the generator is recalibrated on half of the participants and scored on the other half. On the other eight directions filtering is neutral and the encoder itself exceeds GlucoFM by 3.5 points. The device remains linearly decodable after filtering, so the filter removes a device-related component that harms transfer rather than all measurement information. The retained bands improve window AUROC on thirteen of fourteen public task--cohort cells (Holm-adjusted p=0.031) and correlation on fourteen of fifteen clinical endpoints in an external cohort of 9,303 participants.

0.16

Safe Data-Driven Insulin Dosage Decision Based on Physiology-Constrained Gaussian Process Learning

eess.SY ·2026-11-19 ·Deheng Cai, Xiang Lu, Wei Liu, Jing Chen, Linong Ji +1 more
similarity 0.59
Abstract

Multiple daily injections (MDI) therapy is widely adopted by insulin-treated subjects with diabetes mellitus. In this work, we study how to ensure that data-driven model learning is aligned with the underlying physiological principles, and introduce a safe data-driven learning and decision framework for the MDI therapy. To provide credible glucose predictions for the decision, a physiology-constrained Gaussian process learning method is developed for glycemic dynamics modeling by encoding the physiological priors as constraints in the model training. Considering the natural day-to-day cycle of insulin decisions, a prediction-based optimization formulation with an objective function that has a penalty term associated with the previous dosage is employed for the insulin therapy, together with the asymmetric penalties on hyper- and hypoglycemia for safety. The effectiveness of the proposed method is verified using the 10-adult cohort from the FDA-accepted UVA/Padova T1DM simulator, and an advisory mode analysis is also conducted based on the clinical data from 40 type 1 diabetes and 55 type 2 diabetes subjects to indicate the safe and physiologically plausible decisions in the real-life applications.

0.27

GlucoAgent: Personalized Glucose Forecasting from Multimodal Personal Context

cs.AI ·2026-11-03 ·Xingzhi Sun, Hyo Jin Kim, Zhiyuan Wang, Hao Chen
published similarity 0.57
Abstract

Continuous glucose monitors, smartwatches, meal logs, and health profiles form a rich multimodal personal context that can significantly enhance glucose forecasting. However, existing methods struggle to effectively utilize these signals to improve glucose prediction because the relevance of different modalities varies drastically across individuals and time. We present GlucoAgent, an LLM-based agentic system that addresses this challenge through dynamic, case-by-case analysis at inference time. For each forecast, GlucoAgent writes and runs code over an individual's multimodal context and returns predictions with a reason and supporting evidence. The generated programs are highly diverse, ranging from retrieving similar past meals to fitting and back-testing physiological and statistical models. On CGMacros, a multimodal glucose dataset, GlucoAgent outperforms time series foundation models on every forecasting horizon, achieving an average RMSE of 22.5 mg/dL compared to 23.5 mg/dL of Chronos-2, the leading multimodal time series foundation model. Furthermore, GlucoAgent is highly effective at leveraging multimodal data. The addition of multimodal data reduces its average RMSE by 1.4 mg/dL (24.0 mg/dL to 22.5 mg/dL), compared to a marginal 0.3 mg/dL (23.8 mg/dL to 23.5 mg/dL) improvement for Chronos-2. This advantage is most pronounced in challenging post-meal windows, where GlucoAgent uses multimodal context to reduce 60-minute forecast RMSE by 4.6 mg/dL (31.0 mg/dL to 26.5 mg/dL), far exceeding the 0.8 mg/dL (31.9 mg/dL to 31.1 mg/dL) reduction achieved by Chronos-2.

0.33